GSK president adds shares via savings plan

GSK plc (GSK) reports a transaction by senior management under its executive savings plan.

Rhea-AI Filing Summary

GSK plc (GSK) reports a transaction by senior management under its executive savings plan. Maya Martinez-Davis, President, acquired 9.221 notional American Depositary Shares (ADS) of GSK within her GSK Executive Supplemental Savings Plan account at a price of $51.7800 per ADS. The transaction took place on 24 August 2026 on the New York Stock Exchange (XNYS). The filing classifies this as an acquisition of notional ADS rather than a direct market trade.

Key Figures

ADS price: $51.7800 per ADS ADS volume: 9.221 ADS Transaction date: 2026-08-24

3 metrics

ADS price $51.7800 per ADS Price of American Depositary Shares acquired by Maya Martinez-Davis

ADS volume 9.221 ADS Volume of notional ADS acquired within the GSK Executive Supplemental Savings Plan account

Transaction date 2026-08-24 Date of the acquisition of notional ADS reported for the GSK President

Key Terms

PDMR, American Depositary Shares, Executive Supplemental Savings Plan, Legal Entity Identifier

4 terms

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS')"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Executive Supplemental Savings Plan financial

"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan"

Legal Entity Identifier regulatory

"LEI | 5493000HZTVUYLO1D793"

A legal entity identifier (LEI) is a unique, standardized code that functions like a global ID card for businesses and organizations involved in financial markets. It helps investors and regulators reliably identify who is on the other side of a deal, trace ownership and links between firms, and reduce confusion or fraud — improving transparency for reporting, risk assessment, and cross-border trades.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider-related transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that its President, Maya Martinez-Davis, acquired 9.221 notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account at a price of $51.7800 per ADS on 24 August 2026.

Who is the person involved in the disclosed transaction at GSK (GSK)?

The person involved is Maya Martinez-Davis, identified as President at GSK. The notification is described as an initial notification of a transaction related to her executive supplemental savings plan account.

What type of security was involved in the GSK (GSK) executive transaction?

The security is American Depositary Shares (ADS) of GSK, identified with ISIN US37733W2044. The filing describes the event as an acquisition of notional ADS within an executive supplemental savings plan.

At what price and volume were the GSK (GSK) ADS acquired in this transaction?

The filing reports a single transaction with a price of $51.7800 per ADS and a volume of 9.221 notional ADS acquired within Maya Martinez-Davis’s GSK Executive Supplemental Savings Plan account.

On what date and where did the reported GSK (GSK) ADS transaction occur?

The transaction occurred on 24 August 2026 and is reported as having been conducted on the New York Stock Exchange (XNYS), according to the details provided in the notification.

Is this GSK (GSK) transaction part of a larger aggregated set of trades?

No. The filing states that the aggregated information is N/A (single transaction), indicating that this disclosure relates to one specific acquisition of notional ADS rather than multiple combined trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 10:38 AM EDT Accepted by SEC EDGAR 08/26/2026 - 10:37 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$51.7800	9.221
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-08-24
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 26, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc